These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
292 related articles for article (PubMed ID: 28292941)
1. Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer. Willuda J; Linden L; Lerchen HG; Kopitz C; Stelte-Ludwig B; Pena C; Lange C; Golfier S; Kneip C; Carrigan PE; Mclean K; Schuhmacher J; von Ahsen O; Müller J; Dittmer F; Beier R; El Sheikh S; Tebbe J; Leder G; Apeler H; Jautelat R; Ziegelbauer K; Kreft B Mol Cancer Ther; 2017 May; 16(5):893-904. PubMed ID: 28292941 [TBL] [Abstract][Full Text] [Related]
2. Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors. Sommer A; Kopitz C; Schatz CA; Nising CF; Mahlert C; Lerchen HG; Stelte-Ludwig B; Hammer S; Greven S; Schuhmacher J; Braun M; Zierz R; Wittemer-Rump S; Harrenga A; Dittmer F; Reetz F; Apeler H; Jautelat R; Huynh H; Ziegelbauer K; Kreft B Cancer Res; 2016 Nov; 76(21):6331-6339. PubMed ID: 27543601 [TBL] [Abstract][Full Text] [Related]
3. Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody-Drug Conjugate as a Therapeutic for Non-Small Cell Lung and Ovarian Cancers. Lin K; Rubinfeld B; Zhang C; Firestein R; Harstad E; Roth L; Tsai SP; Schutten M; Xu K; Hristopoulos M; Polakis P Clin Cancer Res; 2015 Nov; 21(22):5139-50. PubMed ID: 26156394 [TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen. Wang X; Ma D; Olson WC; Heston WD Mol Cancer Ther; 2011 Sep; 10(9):1728-39. PubMed ID: 21750220 [TBL] [Abstract][Full Text] [Related]
11. EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma. Capone E; Lamolinara A; D'Agostino D; Rossi C; De Laurenzi V; Iezzi M; Iacobelli S; Sala G J Control Release; 2018 May; 277():48-56. PubMed ID: 29550398 [TBL] [Abstract][Full Text] [Related]
12. RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models. Strop P; Tran TT; Dorywalska M; Delaria K; Dushin R; Wong OK; Ho WH; Zhou D; Wu A; Kraynov E; Aschenbrenner L; Han B; O'Donnell CJ; Pons J; Rajpal A; Shelton DL; Liu SH Mol Cancer Ther; 2016 Nov; 15(11):2698-2708. PubMed ID: 27582525 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness of Antibody-Drug Conjugate (ADC): Results of In Vitro and In Vivo Studies. Kang X; Zhou L; Jian YM; Lan SA; Xu F Med Sci Monit; 2018 Mar; 24():1408-1416. PubMed ID: 29515096 [TBL] [Abstract][Full Text] [Related]
14. Monomethyl auristatin E-conjugated anti-EGFR antibody inhibits the growth of human EGFR-positive non-small cell lung cancer. Li Z; Wang M; Yu D; Luo W; Fang J; Huang C; Yao X Cancer Chemother Pharmacol; 2019 Jul; 84(1):61-72. PubMed ID: 31037333 [TBL] [Abstract][Full Text] [Related]
15. Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts. Koga Y; Manabe S; Aihara Y; Sato R; Tsumura R; Iwafuji H; Furuya F; Fuchigami H; Fujiwara Y; Hisada Y; Yamamoto Y; Yasunaga M; Matsumura Y Int J Cancer; 2015 Sep; 137(6):1457-66. PubMed ID: 25704403 [TBL] [Abstract][Full Text] [Related]
16. Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes. Shor B; Kahler J; Dougher M; Xu J; Mack M; Rosfjord E; Wang F; Melamud E; Sapra P Clin Cancer Res; 2016 Jan; 22(2):383-94. PubMed ID: 26319086 [TBL] [Abstract][Full Text] [Related]
17. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Ma D; Hopf CE; Malewicz AD; Donovan GP; Senter PD; Goeckeler WF; Maddon PJ; Olson WC Clin Cancer Res; 2006 Apr; 12(8):2591-6. PubMed ID: 16638870 [TBL] [Abstract][Full Text] [Related]
18. Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers. Hagemann UB; Ellingsen C; Schuhmacher J; Kristian A; Mobergslien A; Cruciani V; Wickstroem K; Schatz CA; Kneip C; Golfier S; Smeets R; Uran S; Hennekes H; Karlsson J; Bjerke RM; Ryan OB; Mumberg D; Ziegelbauer K; Cuthbertson AS Clin Cancer Res; 2019 Aug; 25(15):4723-4734. PubMed ID: 31064781 [TBL] [Abstract][Full Text] [Related]
19. Investigation of Hydrophilic Auristatin Derivatives for Use in Antibody Drug Conjugates. Mendelsohn BA; Barnscher SD; Snyder JT; An Z; Dodd JM; Dugal-Tessier J Bioconjug Chem; 2017 Feb; 28(2):371-381. PubMed ID: 28060485 [TBL] [Abstract][Full Text] [Related]
20. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Challita-Eid PM; Satpayev D; Yang P; An Z; Morrison K; Shostak Y; Raitano A; Nadell R; Liu W; Lortie DR; Capo L; Verlinsky A; Leavitt M; Malik F; Aviña H; Guevara CI; Dinh N; Karki S; Anand BS; Pereira DS; Joseph IB; Doñate F; Morrison K; Stover DR Cancer Res; 2016 May; 76(10):3003-13. PubMed ID: 27013195 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]